Fda accepts mesoblast's biologics license application (bla) for ryoncil® in children with steroid-refractory acute graft-versus-host disease (sr-agvhd)

If approved, ryoncil will be the first allogeneic “off-the-shelf” cellular medicine in the us, and the first cell therapy for children up to 18 years old with sr-agvhd if approved, ryoncil will be the first allogeneic “off-the-shelf” cellular medicine in the us, and the first cell therapy for children up to 18 years old with sr-agvhd
MESO Ratings Summary
MESO Quant Ranking